ITMCTR2200005886尚未招募1 期
A multicenter randomized, double-blind placebo-controlled study of invigorating spleen and Clearing Lung in the treatment of bronchiectasis (spleen deficiency and lung heat syndrome)
适应症
试验速览
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 年龄范围
- 18 至 70（—）
- 性别
- All
入选标准
- •1.Outpatients meeting the diagnostic criteria for stable bronchiectasis; 2. Aged 18-70; 3. TCM syndrome differentiation is lung qi deficiency phlegm heat accumulation of lung; 4 patients with at least one exacerbation in the past 1 year; 5. Those who are willing to comply with the doctor's diagnosis and treatment arrangement and sign the informed consent.
排除标准
- •1.With hemoptysis as the main manifestation of dry bronchioma patients; 2.Patients with pulmonary interstitial fibrosis resulting in tractive bronchiectasis; 3.Patients with active pulmonary tuberculosis and pulmonary fungal infection; 4.Pregnant women or lactating women; 5.History of chronic alcohol or substance abuse or any factors affecting compliance;6.Poor compliance during screening; 7.Complicated with primary diseases of cardiovascular, cerebrovascular, liver, kidney and hematopoietic system; 8.abnormal liver and kidney function: liver (ALT or AST) more than twice the upper limit of normal value or abnormal kidney function (BUN or Cr); 9.mental patients; 10. allergic constitution and allergic to this drug; 11.Participated in other clinical trials within 1 month; 12.Other conditions that the investigator considers inappropriate for inclusion.
研究者
相似试验
进行中（未招募）
不适用
A multicenter randomized, double-blind placebo controlled phase III study of the efficacy of Xaliproden in preventing the neurotoxicity of oxaliplatin in first-line treatment of patients with metastatic colorectal cancer treated with oxaliplatin/5FU/LVEUCTR2005-002570-30-ITSANOFI-SYNTHELABO900
进行中（未招募）
1 期
Phase III trial of specific immunotherapy with allergoid preparation of house dust mite in patients with allergic bronchial asthma and with allergic rhinitis or rhinoconjunctivitisallergic bronchial asthma and allergic rhinitis or rhinoconjunctivitisMedDRA version: 20.0 Level: LLT Classification code 10039097 Term: Rhinoconjunctivitis System Organ Class: 100000004862MedDRA version: 20.0 Level: LLT Classification code 10001705 Term: Allergic asthma System Organ Class: 100000004855MedDRA version: 20.0 Level: LLT Classification code 10001723 Term: Allergic rhinitis System Organ Class: 100000004855EUCTR2015-000188-15-PLAllergopharma GmbH & Co. KG1,390
进行中（未招募）
不适用
A multicenter, randomized double-blind placebo controlled Phase III study of the efficacy of xaliproden in preventing the neurotoxicity of oxaliplatin in first-line treatment of patients with metastatic colorectal cancer treated with oxaliplatin/5-FU/LV. - NAEUCTR2005-002570-30-DEsanofi-aventis recherche & développement900
进行中（未招募）
不适用
A multicenter, randomized double-blind placebo controlled Phase III study of the efficacy of xaliproden in preventing the neurotoxicity of oxaliplatin in first-line treatment of patients with metastatic colorectal cancer treated with oxaliplatin/5-FU/LV. - NAPatients with metastatic colorectal cancer treated with oxaliplatin/5-FU/LVat risk of cumulative peripheral sensory neuropathy (PSN) relative to cumulative dose of oxaliplatin.MedDRA version: 8Level: LLTClassification code 10034620EUCTR2005-002570-30-PTSanofi-Synthelabo Recherche900
进行中（未招募）
1 期
A multicenter, randomized double-blind placebo controlled Phase III study of the efficacy of xaliproden in preventing the neurotoxicity of oxaliplatin in first-line treatment of patients with metastatic colorectal cancer treated with oxaliplatin/5-FU/LV. - NAEUCTR2005-002570-30-HUSanofi-Synthelabo Recherche900